Inhibition of glycosylation prevents H-2K and D antigen expression on SV40 virus-transformed cells.
Tunicamycin, an inhibitor of glycosylation, was used to examine the role of carbohydrate moieties of glycoproteins involved in recognition of Simian virus 40 (SV40)-transformed cells by cytotoxic T lymphocytes (CTL). Tunicamycin treatment renders such cells refractory to lysis by H-2 restricted, SV40-specific CTL as well as by allogeneic CTL directed only against H-2 antigens. Treated cells are no longer susceptible to lysis by anti-H-2 antisera and complement, nor are they stained by monoclonal anti-H-2 antibodies in an indirect immunofluorescence assay. No accumulation of H-2 proteins was detected in immunoprecipitates from cells labeled with [35S]methionine in the presence of tunicamycin. It is concluded that tunicamycin prevents the expression of H-2 glycoproteins in these cells, perhaps due to accelerated degradation of the unglycosylated molecules.
D000818:Animals; D000954:Antigens, Surface / Q000032:analysis; D002472:Cell Transformation, Viral / Q000187:drug effects*; D003602:Cytotoxicity, Immunologic / Q000187:drug effects; D006023:Glycoproteins / Q000378:metabolism*; D006183:H-2 Antigens / Q000032:analysis*; D008325:Mammary Neoplasms, Experimental / Q000276:immunology; D051379:Mice; D008809:Mice, Inbred C3H; D013539:Simian virus 40 / Q000276:immunology; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology; D014412:Tumor Virus Infections / Q000276:immunology*; D014415:Tunicamycin / Q000494:pharmacology
D000954:Antigens, Surface; D006023:Glycoproteins; D006183:H-2 Antigens; C024755:H-2K(K) antigen; D014415:Tunicamycin